Perennial allergic rhinitis

Summary

Perennial allergic rhinitis (MONDO:0024332) is a disease and 73 clinical trials. Top therapeutic interventions include bepotastine, azelastine, and cetirizine. A subtype of allergic rhinitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 73

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	perennial allergic rhinitis
Mondo ID	MONDO:0024332
EFO	EFO:1001417
MeSH	D012221
ICD-11	1273917262
NCIT	C92189
SNOMED CT	446096008
UMLS	C0035457
MedGen	19783
Is cancer (heuristic)	no

Also known as: non-seasonal allergic rhinitis · nonseasonal allergic rhinitis · perennial allergic rhinitis

Disease family

This is a subtype of allergic rhinitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › allergic respiratory disease › allergic rhinitis › perennial allergic rhinitis

Related subtypes (2): seasonal allergic rhinitis, vasomotor rhinitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

6 approved, 19 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Beclomethasone Dipropionate	Approved (phase 4)
Budesonide	Approved (phase 4)
Ciclesonide	Approved (phase 4)
Desloratadine	Approved (phase 4)
Fluticasone Furoate	Approved (phase 4)
Loratadine	Approved (phase 4)
Azelastine	Phase 3 (in late-stage trials)
Bepotastine	Phase 3 (in late-stage trials)
Bilastine	Phase 3 (in late-stage trials)
Cetirizine	Phase 3 (in late-stage trials)
Dexamethasone	Phase 3 (in late-stage trials)
Epinastine	Phase 3 (in late-stage trials)
Epinephrine	Phase 3 (in late-stage trials)
Flunisolide	Phase 3 (in late-stage trials)
Fluticasone Propionate	Phase 3 (in late-stage trials)
Ketotifen	Phase 3 (in late-stage trials)
Levocetirizine	Phase 3 (in late-stage trials)
Mometasone	Phase 3 (in late-stage trials)
Mometasone Furoate	Phase 3 (in late-stage trials)
Montelukast	Phase 3 (in late-stage trials)
Olopatadine	Phase 3 (in late-stage trials)
Prednisone	Phase 3 (in late-stage trials)
Pseudoephedrine	Phase 3 (in late-stage trials)
Syrup	Phase 3 (in late-stage trials)
Triamcinolone	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Carbon Dioxide, Fexofenadine, Levocabastine.

Clinical trials & evidence

Clinical trials

Clinical trials: 73.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	40
PHASE4	14
Not specified	10
PHASE2	4
PHASE1	3
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00359216	PHASE4	COMPLETED	The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
NCT00439712	PHASE4	COMPLETED	Levocetirizine in the Treatment of Nasal Obstruction Due to Perennial Allergic Rhinitis
NCT00491374	PHASE4	TERMINATED	Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)
NCT00590772	PHASE4	COMPLETED	The Role of Montelukast in Rhinitis and Sleep
NCT00641212	PHASE4	COMPLETED	Children, Perennial Allergic Rhinitis (PAR), l-t Growth
NCT00730912	PHASE4	COMPLETED	Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)
NCT00789555	PHASE4	COMPLETED	Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
NCT00794495	PHASE4	COMPLETED	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)
NCT00794599	PHASE4	COMPLETED	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)
NCT00794846	PHASE4	COMPLETED	Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)
NCT00894231	PHASE4	COMPLETED	Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis
NCT01062139	PHASE4	UNKNOWN	Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy
NCT01270256	PHASE4	COMPLETED	NasoNeb Delivery of an Intranasal Steroid
NCT01654536	PHASE4	COMPLETED	A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
NCT06339008	PHASE3	RECRUITING	A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT00163488	PHASE3	COMPLETED	Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)
NCT00163501	PHASE3	COMPLETED	Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
NCT00163514	PHASE3	COMPLETED	Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
NCT00261287	PHASE3	COMPLETED	Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
NCT00578331	PHASE3	COMPLETED	Safety Study of Olopatadine Nasal Spray
NCT00712920	PHASE3	COMPLETED	A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
NCT00720382	PHASE3	COMPLETED	A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
NCT00732368	PHASE3	COMPLETED	A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis (Study P04459)
NCT00783224	PHASE3	COMPLETED	A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
NCT00953147	PHASE3	COMPLETED	A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
NCT00974571	PHASE3	COMPLETED	Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
NCT01018862	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis
NCT01033825	PHASE3	COMPLETED	Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis
NCT01067105	PHASE3	COMPLETED	A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older
NCT01116778	PHASE3	COMPLETED	the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis
NCT01127620	PHASE3	COMPLETED	Efficacy Study for the Symptomatic Treatment of Perennial Allergic Rhinitis With a 1 Year Safety Extension
NCT01133626	PHASE3	COMPLETED	Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)
NCT01228630	PHASE3	COMPLETED	Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.
NCT01287364	PHASE3	COMPLETED	Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
NCT01378429	PHASE3	COMPLETED	Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis
NCT01401465	PHASE3	COMPLETED	Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
NCT01425632	PHASE3	COMPLETED	A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
NCT01451541	PHASE3	COMPLETED	A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
NCT01470053	PHASE3	COMPLETED	Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
NCT01539304	PHASE3	COMPLETED	Clinical Trial to Evaluate the Safety and Efficacy of CITUS Dry Syrup in Children With Perennial Allergic Rhinitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEPOTASTINE	4	7
AZELASTINE	4	5
CETIRIZINE	4	5
CICLESONIDE	4	5
MONTELUKAST	4	5
LEVOCETIRIZINE	4	3
MOMETASONE FUROATE	4	3
BUDESONIDE	4	2
OLOPATADINE	4	2
BECLOMETHASONE DIPROPIONATE	4	1
BILASTINE	4	1
DESLORATADINE	4	1
LORATADINE	4	1
MOMETASONE	3	2
FLUTICASONE	3	1
OZUREPRUBART	2	1
CHEMBL5205127	0	2
CHEMBL249466	0	2
CHEMBL5430305	0	1
CHEMBL1319520	0	1